HOME >> BIOLOGY >> NEWS
Clinical trial data regarding NKTR-061 will be presented at ATS International Conference

San Francisco, Calif. -- Results of a Phase 2a clinical trial evaluating the potential of NKTR-061 (inhaled amikacin) to treat hospital acquired gram-negative bacterial pneumonia will be presented at the American Thoracic Society (ATS) International Conference, May 18 23, 2007, in San Francisco.

WHO: Dr. Michael S. Niederman, MD, Chairman, Department of Medicine, Winthrop-University Hospital, Professor of Medicine; Vice Chairman, Department of Medicine, SUNY at Mineoloa.

Dr. Jean Chastre, Professor of Medicine, University of Paris.

WHAT: Four posters detailing the results of a Phase 2a clinical trial evaluating the pharmacokinetic, serum and tracheal aspirate concentration, safety and antibiotic reduction properties of NKTR-061.

Data will be presented and discussed at this ATS session to show a reduction in the use of IV antibiotics in mechanically ventilated patients during treatment of gram-negative pneumonia with NKTR-061. Further, the data indicate that the administration of NKTR-061 resulted in high tracheal aspirate concentrations and high epithelial lining fluid concentrations of amikacin in gram-negative pneumonia in intubated mechanically ventilated patients. Finally, data will be presented indicating that NKTR-061 achieves safe serum concentrations following multiple dosing in intubated mechanically ventilated patients with gram-negative pneumonia.

WHEN: Monday, May 21st, 2007, 8:15-11:00 am (PT)

WHERE: The American Thoracic Society (ATS) International Conference at the San Francisco Marriott Hotel.

ABOUT NKTR-061:

NKTR-061 (inhaled amikacin) is being tested to evaluate the safety and tolerability of amikacin formulated for inhalation for the adjunctive treatment of gram-negative pneumonia in ventilated patients diagnosed with hospital or ventilator associated pneumonia. This new inhaled antibiotics product candidate leverages N
'"/>

Contact: Tim Warner
twarner@nektar.com
650-283-4915
Nektar Therapeutics
9-May-2007


Page: 1 2

Related biology news :

1. 2007-2008 Genzyme/ACMGF Clinical Genetics Fellowship In Biochemical Genetics award winner announced
2. Scientists honored with Excellence in Clinical Research Award
3. Clinical trial for diabetic macular edema
4. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
5. Research and program highlights of the 2007 Annual Clinical Genetics Meeting, March 21-25, 2007
6. American College of Medical Genetics -- 2007 Annual Clinical Genetics Meeting Announcement
7. October MCP: A special issue on Clinical Proteomics
8. Columbia University Medical Center receives major new NIH Clinical Science investment funds
9. Researchers reverse juvenile diabetes in animal model; Clinical trial FDA approved
10. Clinical trial to test stem cell approach for children with brain injury
11. Vaccine trials inject hope into koalas future

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics Biomedical (ABM), a leading ... for not only the products and treatments developed, but also the dedicated team ... All the brands built by ABM have received several honors already for 2020, ...
(Date:7/2/2020)... , ... July 02, 2020 ... ... Systems, B.V. (MBS) has announced a publication detailing the use of its ... transcription polymerase chain reaction (RT-PCR) in 16 minutes. The article, titled "Ultra-fast ...
(Date:7/1/2020)... VENICE, Calif. (PRWEB) , ... July 01, 2020 ... ... focused on building awareness and solutions for glioblastoma—the most common and aggressive adult ... and Lisa Haile, JD, PhD. Senior Fellows are charged with supporting the organization’s ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... 200 of the top radiation centers in 16 countries, has reached its 20th ... SDX® is now in routine use at top universities including University of Pennsylvania, ...
(Date:7/18/2020)... MILWAUKEE (PRWEB) , ... July 16, 2020 , ... “We ... at Third Wave Bioactives. “It’s the only technology of its kind on the market ... flavor of onions with the protective capacity of traditional cultured ingredients, creating a natural ...
(Date:7/10/2020)... BALTIMORE (PRWEB) , ... July ... ... Baltimore biotechnology company, announced today that Massachusetts Institute of Technology (MIT) has ... This broader license allows PathSensors to move into the point-of-care diagnostic market, ...
(Date:7/7/2020)... , ... July 06, 2020 , ... ... Awards. Entries from Roche, Eli Lilly, Bristol-Myers Squibb, the University of Chicago, Massachusetts ... Bio-IT World has hosted an elite awards program, highlighting outstanding examples of how ...
Breaking Biology Technology:
Cached News: